

October 23, 2025

For Release: Immediately

Refer to: Mitali Gajbhiye; mitali.gajbhiye@network.lilly.com (Eli Lilly and Company)
Heena Kanal; heena.kanal@cipla.com (Cipla Limited)
Diksha Maheshwari; Investor.Relations@cipla.com (Investor relations, Cipla Limited)

**Lilly and Cipla sign a distribution and promotion agreement for Yurpeak®
(tirzepatide) in India**

- Tirzepatide was launched in India by Lilly in March 2025 under the brand name Mounjaro®
- Under this agreement, Cipla will market tirzepatide under the brand name Yurpeak®

New Delhi/Mumbai, October 23, 2025: Eli Lilly and Company (India) Pvt. Ltd. (Lilly), and Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") today announced an agreement to distribute and promote tirzepatide in India under a second brand name, Yurpeak®.

Under the agreement, Cipla has the rights to distribute and promote Yurpeak®—the second brand of tirzepatide in India. This strategic agreement aims to expand the availability of tirzepatide by enabling broader access across the country beyond cities where Lilly already has an established presence. Lilly will manufacture and supply Yurpeak® to Cipla, and the price will be the same as Mounjaro®.

“The introduction of a second brand of tirzepatide in India through our commercial agreement with Cipla furthers Lilly’s commitment to expanding access to innovative treatments for chronic conditions,” said **Winslow Tucker, President and General Manager, Lilly India**. “Our mission—to make life better for people around the world—drives our commitment to accelerate the introduction of innovative medicines and expand access to hard-to-reach communities. With India facing a growing burden of type 2 diabetes and obesity, broader availability of tirzepatide will ensure that more patients can benefit from this innovative therapy.”

Commenting on the agreement, **Achin Gupta, Global Chief Operating Officer, Cipla Limited**, said, “At Cipla, we remain steadfast in our commitment to advancing patient care by facilitating access to the best of global scientific innovation. With the introduction of Yurpeak® (tirzepatide), we are stepping into obesity care with the same commitment and scale that have defined our efforts in respiratory and chronic therapies. Our partnership with Lilly reflects our resolve to address one of the most pressing health concerns of our

time and offer patients innovative, accessible solutions that can transform health outcomes.”

Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, indicated as an adjunct to diet and exercise for the treatment of type 2 diabetes and chronic weight management in adults with obesity (BMI \geq 30) or overweight (BMI \geq 27) with at least one weight-related comorbidity.

Yurpeak® (tirzepatide) will be available in the KwikPen® presentation, a multi-dose single-patient-use prefilled pen. Each pen contains four fixed doses, administered once weekly. The pen will be available in six dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg, allowing healthcare professionals to personalize treatment plans to better suit individual patient needs.

India has about 101 million people living with diabetes and nearly half of these in the adult patients category are being inadequately treated with suboptimal glycemic control.¹ Obesity, a chronic relapsing disease, is a major risk factor for diabetes and linked to more than 200 health complications, including, coronary heart disease, cancer, and obstructive sleep apnea.^{2,3} As of 2023, adult obesity prevalence in India stood at around 6.5%, affecting nearly 100 million people.⁴

About Lilly

Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit [Lilly.com/in](https://www.lilly.com/in), or follow us on [Facebook](#), [Instagram](#) and [LinkedIn](#).

About Cipla

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+

products using cutting-edge technology platforms to cater to our 74+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Mar'25), 2nd largest in the pharma prescription market in South Africa (IQVIA MAT Feb'25), and 4th largest by prescription for Generic inhalation products in the US Gx (IQVIA TRx MAT Mar'25). For almost nine decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility, and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers, and all stakeholders. For more, please visit www.cipla.com, or click on [Twitter](#), [Facebook](#), [LinkedIn](#).

References:

1. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17) - The Lancet Diabetes & Endocrinology .
2. Waters H, Graf M. America's Obesity Crisis: The Health and Economic Costs of Excess Weight. Milken Institute; 2018. Accessed February 20, 2024. <https://milkeninstitute.org/sites/default/files/reports-pdf/Mi-Americas-Obesity-Crisis-WEB 2.pdf>.
3. Wolk R, Shamsuzzaman AS, Somers VK. Obesity, sleep apnea, and hypertension. *Hypertension*. 2003;42(6):1067-1074. doi:10.1161/01.HYP.0000101686.98973.A3.
4. IQVIA analysis and projection based on National Family Health Survey (NFHS-5), India, 2019-20 and Data from Global Observatory (World Obesity)- https://data.worldobesity.org/country/india-95/#data_economic-impact.
5. Rosenstock J, Wysham C, Frias JP, et al. *Lancet* 2021; 398(10295): 143-155.